(Q44606031)

4 December 2017

title

Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study (English)

1 reference

4 December 2017

Is Bicalutamide Equivalent to Goserelin for Prostate Volume Reduction before Radiation Therapy? A Prospective, Observational Study (English)

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00093-1

adaptive radiation therapy

17 March 2024

main subject

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00093-1

17 March 2024

1

A. Henderson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14524484

17 March 2024

author name string

Langley SE

2

1 reference

4 December 2017

S. E M. Langley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14524484

17 March 2024

R. W. Laing

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14524484

17 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14524484

17 March 2024

publication date

1 September 2003

1 reference

full work available at URL

4 December 2017

https://api.elsevier.com/content/article/PII:S0936655503000931?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00093-1

https://api.elsevier.com/content/article/PII:S0936655503000931?httpAccept=text/plain

17 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00093-1

17 March 2024

1 reference

4 December 2017

volume

15

1 reference

4 December 2017

issue

6

1 reference

4 December 2017

page(s)

318-321

1 reference

The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Hormonal cytoreduction and radiotherapy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Prognostic factors in carcinoma of the prostate--analysis of RTOG study 75-06

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Hypoxia in human prostate carcinoma: an Eppendorf PO2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2803%2900093-1

7 January 2021

The barrel-shaped cervical carcinoma

16

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00093-1

Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation

17 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/S0936-6555(03)00093-1

17 March 2024

Identifiers

1 reference

4 December 2017

1 reference